Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies
Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies. // Journal of Investigative Dermatology. – URL: https://www.sciencedirect.com/science/article/pii/S0022202X26038650?dgcid=rss_sd_all
Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies. Journal of Investigative Dermatology. https://www.sciencedirect.com/science/article/pii/S0022202X26038650?dgcid=rss_sd_all
“Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies.” Journal of Investigative Dermatology.
@article{article53703,
title = {Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies},
journal = {Journal of Investigative Dermatology},
url = {https://www.sciencedirect.com/science/article/pii/S0022202X26038650?dgcid=rss_sd_all}
}